Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
One more establishment of the Council of Scientific and Industrial Research (CSIR) has begun entire genome sequencing of the novel coronavirus.
This organization is Chandigarh-based Institute of Microbial Technology (IMTech) and it has taken up the assignment of enormous scope genome sequencing of the infection.
Infections have a higher transformation rate contrasted with that of organisms and their hereditary material continues changing rapidly as they imitate quickly.
These genome sequencing tests will be submitted to the global perceived store,” said IMTech chief Dr Sanjeev Khosla.
CSIR-IMTECH, Chandigarh India
“The total genome succession data will empower scientists to pick up bits of knowledge about the starting points of the infection, the various sorts of strains flowing in India and how it has spread over the length and broadness of our nation,” he said.
“The genomic asset acquired from this sequencing will likewise permit distinguishing proof of new focuses for determination and medications for COVID-19,” he further included.
Entire genome sequencing is a technique used to decide the total DNA succession of a particular life form’s genome.
As the Institute is known for its specialization in microbial and genomic examine, CSIR-IMTech will perform sequencing of the SARS-Cov-2 RNA genome segregated from clinical examples.
Up until this point, 9000 examples have been sequenced universally according to worldwide Initiative on Sharing All Influenza Data (GISAID) — an open stage began by the WHO in 2008 for nations to share genome arrangements.
The genomic asset acquired from this sequencing will likewise permit the recognizable proof of new focuses of analysis and medications for COVID-19.
“We have just begun clinical testing of tests and now by leaving on this crucial succession viral strains, we will be better prepared to comprehend the idea of this infection, which has caused a worldwide pandemic,” Dr Khosla included.
CSIR-IMTech will utilize its involvement with compact, ongoing and direct genome sequencing to consider the concoction change in SARS-Cov-2 strains from India.
